.antagonists, vari ations in GFR were unrelated to changes in BP.
T he incidence and prevalence of renal failure secondary to diabetes mellitus has increased steadily during the past decade in the United States 1 ; therefore, diabetes is now the lead ing cause of end-stage renal disease. 2 Microalbumin uria (30 to 300 mg/24 h) predicts overt nephropathy (proteinuria >300 mg/24 h) and chronic renal failure in diabetic individuals. 3 It has also a powerful asso ciation with macrovascular disease, which is unex plained by simultaneous existing cardiovascular risk factors. 4 Among the 35% of patients with insulin-dependent diabetes mellitus (IDDM) who will develop nephrop athy, persistent microalbuminuria ("incipient ne phropathy") appears 5 to 10 years after the onset of diabetes. It usually progresses to the stages of overt nephropathy and later on to end-stage renal fail ure. 5, 6 Hypertension contributes to the progression of diabetic nephropathy in IDDM. 7 Blood pressure (BP) is usually normal in the absence of nephropathy, tends to rise before or concomitantly with the onset of incipient nephropathy, and increases further when renal damage progresses to the stages of clinical ne phropathy and renal failure.
5,8,9
In patients with non-insulin-dependent diabetes mellitus (NIDDM), the temporal relationship between the onset of hy pertension and nephropathy, respectively, is more variable; hypertension most often precedes and sometimes follows diabetes. On the one hand, pro gression of nephropathy aggravates hyperten sion, 10, 11 but on the other hand once nephropathy is present, a high BP may also promote and accelerate the development of renal failure. 10 Compared with the general population, relative mortality from car diovascular disease is increased about fivefold in di abetics with hypertension 12, 13 and about 35-fold in diabetics with clinical nephropathy. 7, 14 Attempts at slowing progression of overt diabetic nephropathy have included dietary modifications and antihypertensive therapy. Severe restriction of protein intake may slightly retard progression to re nal failure, 15 but the feasibility and acceptability of this dietary modification are even more problematic in diabetic than in nondiabetic patients. Several stud ies during the past 15 26 In an attempt to resolve the controversy around this possibility, we reported a meta-analysis of published studies in diabetics with microalbumin uria or overt proteinuria treated with conventional agents, angiotensin-converting enzyme (ACE) inhib itors, or Ca 2+ antagonists.
27,28
Here, we present an updated meta-analysis of treatment-effects concern ing not only proteinuria but also GFR.
METHODS
Studies and Experimental Groups The literature was screened for clinical trials using any antihyper tensive agents in diabetic patients. The search was performed using MEDLINE and publications and ab stracts of recent major congresses. Studies fulfilling the following criteria were included in our previous report 28 and the present analysis: 1) diabetic patients receiving conventional antihypertensive drugs (di uretics and/or β-blockers and sometimes also hydralazine-type vasodilators) or a monotherapy with ACE inhibitors or Ca Statistical Analysis Study end-points were mean arterial BP (mm Hg), GFR (mL/min), and urine pro tein excretion defined as either albumin or total pro tein excretion ^g/min). Each end-point consisted of two values, one at baseline and one after treatment. The relative change of the mean (expressed as per centage) between these two timepoints was used for analysis. In studies with more than one measurement after >4 weeks of treatment duration, the mean value was used.
Statistical analyses were performed using the soft ware package of the SAS Institute (Cary, NC). 29 Ef-fects of antihypertensive therapy on urinary albumin or protein excretion, mean BP and GFR were calcu lated separately for the different classes of agents. Treatment effects were weighted by the number of patients in each report in relation to the total number of patients and number of reports, and mean values and 95% confidence intervals (CI) were calculated. Differences between the drug-specific classes were tested by analysis of variance and were considered significant at Ρ < .05 (two-tailed). Multiple regression analysis was applied to determine the influence of different independent explanatory variables on study end points. Type of medication, initial mean BP, ini tial urinary albumin or total protein excretion, type of diabetes, duration of the study, and number of pa tients investigated were considered as independent variables. Forward stepwise regression analysis was then performed for each treatment group to identify which of the independent variables could be explan atory for renal effects. Linear regression analysis was carried out using change in mean BP, initial mean BP, or initial level of albumin or total protein excretion as independent variables and change in urinary albumin or total protein excretion and change in GFR, as de pendent variables. ANOVA was used to compare the differences between the agent-specific groups. F-test for equal variances in groups with different sample sizes did not reveal any violation of the ANOVA as sumptions. The statistical difference of the final re gression lines were calculated using a model as de scribed by Kleinbaum et al. 30 Change in Mean Blood Pressure, Δ%
RESULTS

Study
FIGURE 2. Percentage changes in albuminuria-proteinuria as related to blood pressure changes in diabetics on "conventional"
drugs. The majority of studies investi gating the renal hemodynamics of dihydropyridines showed no effect of nifedipine on efferent arteriolar resistance. 75 Therefore, a beneficial influence of low ered systemic BP on glomerular pressure may be an tagonized by preferential afferent over efferent glo merular vasodilatation, which occurs with certain Ca 
24,81
On the other hand, the lack of effect of nifedipine on albumin excretion may depend, perhaps in part, on proximal tubular inter actions. 46 Nifedipine caused a marked reduction in fractional lithium reabsorption and a corresponding increase in lithium clearance. 82 32-Microglobulin, a freely filterable protein and, therefore, also used as a marker of proximal tubular function, 83 was signifi cantly increased during nifedipine treatment com pared with lisinopril therapy.
46,84
The inhibitory ef fect of nifedipine on several proximal tubular func tion markers is consistent with the possibility that it might also inhibit proximal tubular albumin reabsorp tion, thereby promoting albuminuria despite its sys temic antihypertensive effect.
As ACE inhibitors exert a specific antiproteinuric effect even without a change in systemic BP ( Figure  5) found a 3.8 times higher cardiovascular mortality rate in patients treated with diuretics alone than in diabetic patients with untreated hypertension; the cardiovascular mor tality rate was increased in diuretic-treated diabetic subjects with or without clinical proteinuria. On the other hand, it was calculated that in the very highrisk group of patients with diabetic nephropathy, ef fective BP control might possibly reduce 10-year mor tality rates from 65 to 20%. 91 In the first large pro spective trial on prognosis, long-term ACE inhibition with captopril in overt diabetic nephropathy has just been reported to reduce markedly their combined risk of mortality or needing dialysis or transplanta tion. 92 These data underline the achievable long-term benefits of effective drug treatment on the prognosis in a special high-risk group of patients. 
